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Abstract 
Objective: To examine treatment utilization patterns and safety of onabotulinumtoxinA for the 
prophylactic treatment of chronic migraine in routine clinical practice.  
Background: Clinical trials support onabotulinumtoxinA for the prophylaxis of headache in 
patients with chronic migraine, but real-world data are limited.  
Design/Methods: A prospective, observational, post-authorization study in adult patients with 
chronic migraine treated with onabotulinumtoxinA. Data were collected at the first study 
injection and approximately every 3 months for ≤52 weeks for utilization and ≤64 weeks for 
safety data, and summarized using descriptive statistics. 
Results: Eighty-five physicians (81% neurologists) at 58 practices in the United Kingdom, 
Germany, Spain, and Sweden participated, and recruited 1160 patients (84.2% female, median 
age 46.6 years). At baseline 85.8% had physician diagnoses of chronic migraine/transformed 
migraine and patients reported an average of 11.3 (SD=6.9) severe headache-days per 28 days; 
50.6% had previously used onabotulinumtoxinA for chronic migraine. A total of 4017 study 
treatments were observed. The median number of injection sites (n=31) and total dose (155U) 
were consistent across all treatment sessions with a median 13.7 weeks observed between 
sessions. At least one treatment-related adverse event was reported by 291 patients (25.1%); the 
most frequently reported treatment-related adverse event was neck pain (4.4%). Most patients 
(74.4%) were satisfied/extremely satisfied with onabotulinumtoxinA treatment. 
Conclusions: Patient demographics/characteristics are consistent with published data on the 
chronic migraine population. Utilization of onabotulinumtoxinA treatment for chronic migraine 
appears to be consistent with the Summary of Product Characteristics and published PREEMPT 
injection paradigm. No new safety signals were identified. 
Keywords: Chronic headache, utilization, adverse events, safety, PREEMPT paradigm 
  
Introduction 
The pharmacologic management of chronic migraine, defined as headache occurring on at least 
15 days per month for >3 months in which headache with features of migraine occur on ≥8 days 
per month,1 includes acute treatment of headaches as well as preventive therapies to reduce the 
frequency of headaches and related migraine disability.2 Chronic migraine has been estimated to 
affect approximately 1.4% to 2.2% of the population globally,.3 with rates of 0.4% to 2.0% 
reported for German populations depending on how strictly the criteria for chronic migraine 
were applied.4 As chronic migraine is often associated with substantial disability, functional 
impairment, and decreased quality of life,5,6 and in many cases may be associated with 
medication overuse,7 it is important that any treatment is both effective and well tolerated. 
The efficacy and safety of onabotulinumtoxinA has been demonstrated in the Phase III Research 
Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials.8,9 In a pooled analysis of four 
double-blind placebo-controlled trials, onabotulinumtoxinA was safe and well tolerated, with 
3.4% of patients discontinuing treatment with onabotulinumtoxinA due to an adverse event.10 
Serious adverse events occurred in 5.4% of patients receiving onabotulinumtoxinA and 3.0% of 
those receiving placebo. Consistent with the known tolerability profile of onabotulinumtoxinA, 
the most frequently reported adverse events in the pooled analysis were musculoskeletal in origin 
and were comparable to the known adverse events associated with onabotulinumtoxinA when 
used in other indications. 
OnabotulinumtoxinA is approved for the prophylaxis of headache in adults with chronic 
migraine.10,11 There are limited data on the utilization and safety of onabotulinumtoxinA for 
chronic migraine in a clinical setting. Therefore, the goal of this study was to monitor the 
utilization practices and describe the safety profile of onabotulinumtoxinA for chronic migraine 
headache prophylaxis in routine clinical practice settings in Europe and was part of post-
authorization regulatory commitments. 
Methods 
Study Design/Physician Recruitment 
This was a prospective, observational, multinational European study (NCT01432379). The study 
protocol was reviewed and approved by the relevant ethics committees in each country. 
Physicians were recruited for the study in the United Kingdom, Germany, Sweden, and Spain 
primarily through attendance at training sessions on the administration of onabotulinumtoxinA 
for the management of chronic migraine educational meetings. 
Patient recruitment was targeted to begin 12 months after regulatory approval in each country, 
with the first recruitment in the United Kingdom on September 9, 2011. The recruitment period 
was 27 months in the United Kingdom, 16 months in Germany, and 14 months in Spain and 
Sweden. Patients were followed up for up to 64 weeks after the baseline treatment, with the last 
follow-up visit scheduled for approximately 12 weeks after the final study treatment session at 
48 to 52 weeks. The total duration of the study from the first patient enrollment through to the 
final follow-up visit for the last patient was 43 months in the United Kingdom, 31 months in 
Germany, 27 months in Sweden, and 28 months in Spain. The last patient’s final follow-up visit 
was conducted in Spain on April 18, 2015.  
Study Population 
The study population consisted of patients receiving onabotulinumtoxinA therapy for chronic 
migraine, recruited by their participating physicians. Patients were adults aged 18 years and older 
with a new or established physician-diagnosis of chronic migraine. All patients were being 
treated for chronic migraine headache in routine practice and could have been new to treatment 
with onabotulinumtoxinA for chronic migraine (treatment naïve) or could have been previously 
treated with onabotulinumtoxinA (non-naïve). The decision to initiate or continue treatment was 
independent of the patients’ enrollment in the study. Written informed consent was provided by 
all participating patients. 
OnabotulinumtoxinA Exposure 
Patients were administered onabotulinumtoxinA in routine clinical practice for the treatment of 
chronic migraine. Although participating physicians were provided with the Summary of Product 
Characteristics, the study protocol did not mandate the treatment paradigm or frequency of 
administration as outlined in the Summary of Product Characteristics. The intent of the study 
was to observe treatment utilization and safety in real-world clinical practice with no study 
intervention. 
According to the Summary of Product Characteristics, the recommended dose of 
onabotulinumtoxinA is 155 U, up to a maximum dose of 195 U, administered intramuscularly 
using a 30-gauge, 0.5-inch needle as 0.1 mL (5 U) injections into 31 to 39 sites, every 12 
weeks.12 The injections are recommended to be divided across 7 specific head and neck muscle 
areas (ie, frontalis, corrugator, procerus, occipitalis, temporalis, trapezius, and cervical paraspinal 
muscle group) and are recommended to be injected bilaterally with the exception of the procerus 
which requires 1 midline injection. In the case of predominant pain location(s), additional 
injections can be administered in up to 3 specific muscle areas (ie, occipitalis, temporalis, and 
trapezius).12 
Data Sources and Measurement 
Practice and physician characteristics were collected at baseline via a questionnaire that captured 
details including practice type and characteristics, physician experience and number of patients 
seen. Patient demographics and clinical characteristics were also collected at baseline. Medical 
and migraine-related history at baseline was captured from the patient’s medical record. 
Treatment utilization information was collected at every treatment session for up to 52 weeks, 
and included details on onabotulinumtoxinA dose, number and location of injections and needle 
size. Detailed information on any adverse events and specific adverse events of special interest, 
including worsening of migraine and intractable migraine, reported by patients and occurring 
during or between treatment sessions was collected throughout the study period. Information 
pertaining to dysphagia was also collected. A final follow-up visit was conducted approximately 
12 weeks after the final treatment session and collected data on adverse events that occurred after 
the final treatment session in addition to patient reported overall satisfaction with 
onabotulinumtoxinA treatment, measured by a single question using a 5-point scale from 
extremely satisfied to extremely dissatisfied.  
Study Size 
This study was not designed for hypothesis testing; therefore, no formal power calculations were 
performed. The number of patients was chosen based on a practical basis in conjunction with the 
ability to detect rates of adverse events similar to those in phase 3 trials undertaken previously. 
With agreement from the Medicines and Health Product regulatory agents in the United 
Kingdom and the Irish Medicines Board, the final overall study enrollment was targeted at 900 
patients, which targeted 320-350 in the United Kingdom, 250-280 in Germany, 200-210 in 
Sweden, and 70-125 in Spain. 
Statistical Analysis 
Data were summarized using descriptive statistics and stratified by country and prior 
onabotulinumtoxinA use. As the analysis was descriptive in nature, statistical inference was not 
performed. Any missing data were excluded from the analysis. Safety data were summarized 
using terminology from the Medical Dictionary for Regulatory Activities (MedDRA version 
17.1). For each system organ class and preferred term, the number and percentage of patients 
who experienced adverse events were tabulated. Patients experiencing more than one adverse 
event were counted only once at each MedDRA level. Incidence rates of adverse events were 
calculated as the number of new events occurring during the study period divided by the person-
time at risk and displayed with 95% exact Poisson confidence intervals.  
The analysis population for physicians included the principal investigator at each site and any 
additional physicians/healthcare professionals administering injections to study patients at that 
site. The analysis population for patients included all patients enrolled in the study who 
completed at least one onabotulinumtoxinA treatment session.  
Results 
Practice Site and Physician Characteristics 
A total of 97 physicians completed the site feasibility questionnaire and 85 physicians at 58 sites 
participated in the study (Figure 1).  There were 19 physicians from 16 practice sites in the 
United Kingdom, 39 physicians from 19 sites in Germany, 14 physicians from 12 sites in 
Sweden and 13 physicians from 11 sites in Spain. Among participating sites, 71.4% were 
specialty-based practices (specialty practice, 32.1%; headache specialty, 26.8%; headache/pain 
clinic, 12.5%), 50.0% were hospital-based practices or based in hospital outpatient clinics, and 
21.4% were general practice or ambulatory care practices (Figure 2). Practice characteristics 
varied across countries, with specialty practice more common in Sweden, and general 
practice/ambulatory care settings more common in Germany and Spain (Supplementary Figure 
1). 
Approximately 75% of the practices saw ≥11 patients with chronic migraine in the 3 months 
prior to the study. The majority of the participating physicians were identified as neurologists 
(81.2%; Figure 2); 75 participating physicians (88.2%) had previous experience treating patients 
with onabotulinumtoxinA for chronic migraine. The average number of years the physicians 
were licensed was 18.5 (SD, 9.4) years. The majority of physicians (67, 78.8%) had attended 
onabotulinumtoxinA training for chronic migraine and 75 (88.2%) had previously prescribed 
onabotulinumtoxinA for chronic migraine. Considerable inter-country variability was observed 
from a mean (SD) of 21.4 (22.6) patients treated per physician in Germany to 222.7 (299.0) 
patients treated in Spain 
Patient Characteristics 
A total of 1168 patients enrolled in the study and 1160 completed at least one treatment session 
(the analysis patient population). Of these, 783 (67.5%) patients completed the entire 52-week 
observation period and final interview (Figure 3). A total of 346 (29.8%) patients were treated 
for less than the maximum 52-week observation period; of these 34 patients were lost to follow-
up. Of the 312 patients who provided a reason for discontinuing treatment, the most common 
reason was lack of efficacy (n=164, 14.1% of the analysis population; Table 1).  
Patients in the analysis population were on average 46.6 (SD, 11.8) years of age, primarily 
female, and white (Table 2). Based on the patient’s medical records, 85.8% of patients had a 
history of chronic migraine or transformed migraine diagnoses, 51.6% had a documented 
diagnosis of migraine and 24.7% had a documented diagnosis of medication overuse. At 
baseline, in a usual month (defined as 28 days) patients reported experiencing an average 7.7 
(SD, 6.9) headache-free days, 9.0 (SD, 6.5) days with headache of mild pain intensity and 11.3 
(SD, 6.9) days with headache of severe pain intensity. Most patients were receiving acute or 
preventive headache medications at baseline, with nearly half (43.9%) indicating being on ≥1 
acute and ≥1 preventive treatment. In addition, half of the patients (n=587, 50.6%) indicated 
having used onabotulinumtoxinA treatment for chronic migraine in the past. Patient 
characteristics at baseline were similar in the treatment-naïve subgroup (Table 2). 
OnabotulinumtoxinA Utilization 
A total of 4017 onabotulinumtoxinA treatment sessions were administered to patients throughout 
the course of the study, with up to seven treatment sessions per patient. Because only one patient 
(in Sweden) received a seventh treatment, data are presented on six treatment sessions (Table 3). 
The median total number of sites injected for each side (right and left) across muscle areas and 
across all treatment sessions was 15 sites, with 1 site on the midline also injected (median total 
number of sites injected was 31 for all treatment cycles 1 to 5). The median total dose of 
onabotulinumtoxinA administered across all treatment sessions was 75 U for each side (right and 
left) and 5 U in the midline (combined median total dose of 155 U). The median injection sites 
and doses were similar across all countries and were the same for treatment-naïve patients as for 
the overall analysis population (Supplementary Table 1). The majority of injections were 
administered using a 0.5 in/1.25 cm needle length. The muscle areas injected across treatment 
sessions were consistent, with the majority of physicians injecting the seven recommended 
muscle areas (Table 4). The muscle areas injected were similar for the treatment-naïve subgroup 
(Supplementary Table 2). The average number of weeks between treatment sessions was 14.3 
(SD, 3.19) weeks and ranged between 6.0 and 51.4 weeks with the average time between 
treatment sessions generally decreasing slightly with each subsequent treatment session (Figure 
4).  
For the purposes of the study, a deviation from the treatment paradigm recommended in the 
Summary of Product Characteristics was defined as a dose of <155 U or >195 U; injection of 
<31 or >39 sites; a dosing interval of < 11 or > 13 weeks, or use of a needle of length other than 
1.25 cm (0.5 in) or 2.5 cm (1 in) for any treatment session; there could be more than one reason 
for deviation from the recommended label treatment paradigm. If a patient received a treatment 
with any of these characteristics at any time during the study period, the patient was classified as 
“deviated” regardless of other treatment sessions. 
Overall, 1045 (90.1%) patients in the study were observed to have ≥1 treatment deviation. 
Patients in the United Kingdom were least likely to receive treatment that deviated from the 
recommended label treatment paradigm (80.1%) and those in Spain were most likely to do so 
(99.1%; Supplementary Table 3). The majority of the deviations documented were deviations 
from the recommended dosage schedule, with 844 (72.8%) patients receiving treatment at an 
interval greater than 13 weeks. In review of treatment deviations during the study, where ≥1 
deviation was reported over the course of up to 6 treatment sessions, nearly half of the patients 
(n=480, 41.4%) were administered a dose <155 U during at least one treatment session. A total 
of 54 (4.7%) patients received a dose >195 U during at least one treatment session; however, 626 
(54.0%) patients did not have any dose deviations at any treatment session (ie, received between 
155 U and 195 U). A third of the patients (n=362, 31.2%) received onabotulinumtoxinA into <31 
sites during at least one treatment session and a quarter (n=299, 25.8%) were injected with a 
needle length outside of recommendations.  
Adverse Events 
A total of 478 (41.2%) patients reported ≥1 adverse event during the study for an overall 
incidence rate of 53.8 per 1000 patient months (95% CI, 49.0–58.8; Table 5). The incidence of 
reported adverse events was lowest in Spain (31.8 per 1000 patient months [95% CI, 24.9–40.1]) 
and Sweden (45.7 [95% CI, 36.5–56.4]) and highest in Germany (65.3 [95% CI 54.3–77.9]) and 
the United Kingdom (68.8 (95% CI, 59.5–79.1]). Treatment-related adverse events were reported 
by 291 (25.1%) patients, resulting in an overall incidence rate of 27.9 per 1000 patient months 
(95% CI, 24.7–31.2) that varied from 9.9 per 1000 patient months (95% CI, 6.4–14.5) in Spain to 
42.1 per 1000 patient months (95% CI 35.3–49.7) in the United Kingdom. OnabotulinumtoxinA 
treatment was stopped due to a treatment-related adverse event in 51 (4.4%) of patients (Table 
5). A serious adverse event was reported by 61 (5.3%) patients and 1 (0.1%) patient reported a 
treatment-related serious adverse event (worsening of migraine). Fatal adverse events were 
reported in 2 (0.2%) patients (1 patient with myocardial infarction and 1 patient with metastatic 
lung neoplasm); neither was considered related to treatment. Of the 54 patients who received 
>195 U during ≥1 treatment session, 22 (40.7%) patients reported ≥1 adverse event. The adverse 
event rate in this population was consistent with the total study population. Overall, the 
percentage of patients reporting ≥1 adverse event declined with each subsequent treatment 
session, with 311/1160 (26.8%) patients reporting ≥1 adverse event at treatment session 1 and 
39/210 (18.6%) patients doing so by treatment session 5.  
For the adverse events of special interest, worsening of migraine occurred most frequently (101 
of 1160 patients, 8.7%) and was considered serious in 6 (0.5%) patients.  The highest percentage 
of patients reporting ≥1 worsening of migraine event was observed in Spain (12.5%) and the 
lowest in Sweden (5.5%). Intractable migraine occurred in 20 (1.7%) patients, and was 
considered serious in 3 (0.3%) patients. Hypersensitivity reactions, none of which were serious, 
occurred in 17 (1.5%) patients and dysphagia in 5 (0.4%). The most commonly reported 
treatment-related adverse event of special interest was worsening of migraine (n=46, 4.0%). All 
other treatment-related adverse events of special interest were reported in <1% of the study 
population (Table 5).  
The most commonly reported treatment-related adverse event was neck pain (n=51, 4.4%; Table 
6). The proportion of patients reporting ≥1 adverse events and treatment-related adverse events 
observed in the treatment naïve population were similar to those observed in the overall study 
population (Table 6). 
Patient Satisfaction with Treatment 
Overall, 1090 patients responded to the treatment satisfaction question, during the final interview 
(n=783 for those completing 52 weeks of treatment and n=307 for those treated less than 52 
weeks). The majority of patients (74.4%) expressed satisfaction (extremely satisfied/satisfied) 
with onabotulinumtoxinA treatment for chronic migraine (Figure 5a). Patient-reported 
satisfaction differed by country; the proportion of patients extremely satisfied/satisfied was 
lowest in Germany (61.3%) and highest in Spain (86.0%). Patient-reported satisfaction differed 
according to whether patients completed the entire 52-week observation period (90.1% [705/783] 
extremely satisfied/satisfied) or were treated for less than 52 weeks (34.5% [106/307] extremely 
satisfied/satisfied) (Figure 5a). Satisfaction among patients who had previously received 
onabotulinumtoxinA treatment was higher than the satisfaction observed with treatment-naïve 
patients (Figure 5b).  Among those who were treatment-naïve, 338 of 519 (65.1%) were 
extremely satisfied/satisfied with treatment. The proportion of patients reporting satisfaction with 
treatment was lower among treatment-naïve patients who were treated for less than the 52-week 
study period (46/183, 25.1%) than among those who were treated for the full 52 weeks (292/336, 
86.9%).  
Discussion 
The safety and efficacy of onabotulinumtoxinA has been established in controlled trials;8,9 
however, real-world data in an actual clinical setting are limited. This study examined the 
utilization patterns and safety of onabotulinumtoxinA in a routine clinical setting. As such, 
efficacy and effectiveness were not specifically examined. Consistent with other published 
studies of chronic migraine, the majority of patients in the study had a diagnosis of chronic 
migraine at their baseline visit.6,10,13-16 Although other diagnoses were also recorded, it is likely 
that migraine and chronic migraine diagnoses overlapped, in addition to tension-type headache 
and medication overuse headache. Overall, patient demographics and clinical characteristics 
align with typical chronic migraine characteristics; therefore, this study was successful in 
enrolling and observing chronic migraine patients in a real-world setting. 
The doses and muscle areas injected were generally consistent across treatment sessions and with 
the Summary of Product Characteristics and PREEMPT injection guidelines.12,17 Approximately 
half of the patients received the recommended 155 U to 195 U dose during all of their treatment 
sessions. Of those treatments that deviated from the recommended paradigm, the majority 
(72.8%) deviated due to longer treatment intervals (ie, >13 weeks between treatments). Although 
approximately 41% of patients received doses <155 U, this may be an artifact of packaging 
restrictions for onabotulinumtoxinA (availability of 50 U, 100 U or 200 U vials only). Indeed 
205 patients (17.7%) received exactly 150 U of onabotulinumtoxinA in ≥1 treatment session. As 
this was an observational study of routine clinical practice in which the treatment schedule was 
not specified and instead depended on physicians’ judgment and patient preferences, variability 
in treatment intervals is to be expected.  
Adverse events were consistent with the product label and with the results from the PREEMPT 
trials.8,9,12,18 The percentage of patients reporting ≥1 adverse event was generally lower than that 
reported from previous pooled registration studies (41.2% vs 72.9%),10 but the percentage of 
patients with ≥1 serious adverse event was similar (5.3% vs 5.4%).10 A reported adverse event 
rate in a clinical practice setting lower than that reported in a controlled study environment is in 
line with the expectation that adverse event reporting would be less stringent in an observational 
study than in a clinical trial. The observed findings also suggest that patients or physicians could 
have tended to under-report non-serious adverse events. 
Although the overall incidence of adverse events was lower in our observational study, the 
nature of the most frequently reported adverse events was similar to that reported in clinical trials 
and included neck pain, muscular weakness, headache, facial paresis and musculoskeletal 
stiffness.  
In general, the adverse event incidence rate decreased with each subsequent treatment session, a 
finding also reported by Diener et al in a pooled analysis of PREEMPT trials.10 It is likely that 
the reduction in adverse events reflects the fact that patients experiencing fewer benefits and 
experiencing adverse events discontinued treatment sooner than those with higher perceived 
benefit and greater tolerability. The observation that many patients with adverse events 
continued treatment with onabotulinumtoxinA suggests that these patients experienced a degree 
of satisfaction/benefit with treatment that outweighed the reported adverse event.  
Adverse events associated with potential distant spread of toxin were also assessed, using a 
conservative approach where all potential cases were counted. No new or unexpected findings 
were reported from this assessment.  
Although the evaluation of efficacy data was not the objective of this observational study, results 
of the one question on patient-reported satisfaction obtained during the final follow-up interview 
revealed an overall high level of patient satisfaction by those patients who completed the entire 
52-week observational period and attended the final interview. In a post-hoc analysis stratified 
by prior treatment status, the subgroup of patients who had previously received 
onabotulinumtoxinA for chronic migraine reported higher satisfaction (83.6% of those using 
onabotulinumtoxinA in the previous 6 months were extremely satisfied or satisfied) than the 
treatment-naïve subgroup of patients (65.1% were extremely satisfied or satisfied). It should be 
noted that patients in these subgroups had a varying number of treatment cycles; typically at least 
2 to 3 treatment cycles repeated every 12 weeks are required to determine responsiveness to 
onabotulinumtoxinA in patients with chronic migraine.19 Because stratification by prior 
treatment status was a post-hoc analysis, these results should be interpreted with caution. 
Treatment-naïve patients may provide a more accurate “real-world” indication of satisfaction for 
people new to treatment with onabotulinumtoxinA.  
This study is not without its limitations. The design of this study allowed for the observation of 
onabotulinumtoxinA utilization in actual clinical practice from a diverse sample of physicians 
and practices, which may increase the generalizability of the data. However, the majority of the 
physicians were specialists with prior experience with onabotulinumtoxinA for chronic migraine; 
therefore, the data may more closely reflect results from specialists who have previously treated 
patients with onabotulinumtoxinA in the countries studied than clinicians new to using the 
therapy. In addition, the study population included both patients who were treatment-naïve and 
those who had previously used onabotulinumtoxinA for chronic migraine. These two groups can 
have a different safety experience. It has been shown that for many therapeutic products, the rate 
at which adverse events occur varies with time, with increased risk occurring early after the 
initiation of therapy.20 As the study was initiated so soon after market authorization approval in 
each of the participating countries, it was unexpected that >50% of patients would have 
previously received onabotulinumtoxinA for chronic migraine. As a result of this unexpected 
finding, we stratified safety results on prior use of onabotulinumtoxinA in a post hoc analysis. 
Those who had used onabotulinumtoxinA within the 6 months before the study also had a lower 
incidence rate per 1000 person-months of discontinuation of treatment due to an adverse event 
2.4 (95% CI, 1.3–4.0) than did the treatment-naïve subgroup 5.2 (95% CI, 3.6–7.4). Again, due 
to the post-hoc nature of this analysis, these results must be interpreted with caution. 
Those patients who had experienced positive results and tolerable adverse events after prior 
treatment with onabotulinumtoxinA would be more likely to be treated than patients who either 
experienced poor clinical outcomes or intolerable adverse events. Patients who were treatment- 
naïve therefore arguably provide data which may be more generalizable to new users of 
onabotulinumtoxinA in a real-world clinical setting. However, a real-world setting would likely 
include a mix of patients (naïve and non-naïve); hence to observe utilization in a routine clinical 
practice we included a mix of patients in our study. Finally, with regards to safety data, the 
observed adverse events and incidence rate of adverse events were consistent with the Summary 
of Product Characteristics and previously published results.  
Overall, this study captured utilization and safety data from a large population of chronic 
migraine patients treated primarily in headache or pain specialty clinics or at hospital based 
practices across 4 countries in Europe, providing a comprehensive look at real-world practices of 
onabotulinumtoxinA for the prophylactic treatment of chronic migraine in these practice settings. 
To our knowledge, this is the largest observational study to date examining utilization and safety 
of onabotulinumtoxinA for chronic migraine in actual clinical practice. Results from this study 
indicate that real-world utilization of onabotulinumtoxinA for chronic migraine appears to be 
consistent with the recommendations in the Summary of Product Characteristics and the 
published PREEMPT injection paradigm. No new safety signals were identified in this study and 
the data continue to support the favorable safety profile of onabotulinumtoxinA for chronic 
migraine headache prophylaxis. 
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Clinical Implications 
• Results from this study indicate that real-world utilization of onabotulinumtoxinA for 
chronic migraine appears to be consistent with the recommendations in the Summary of 
Product Characteristics and the published PREEMPT injection paradigm.  
• No new safety signals were identified in this study and the data continue to support the 
favorable safety and tolerability profile of onabotulinumtoxinA for chronic migraine 
headache prophylaxis. 
• The majority of patients reported they were satisfied or extremely satisfied with 
onabotulinumtoxinA treatment for chronic migraine. 
• This study was able to capture utilization and safety data from a large population of 
chronic migraine patients across 4 countries in Europe, providing a comprehensive look 
at real-world practices of onabotulinumtoxinA for the prophylactic treatment of chronic 
migraine. 
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Figure 3. Patient enrollment and disposition. 
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 Figure 4. Mean (+SD) Time Between OnabotulinumtoxinA Treatment Sessions 
 
NOTE: Dotted line indicates recommended treatment interval of 12 weeks between treatment sessions. Descriptive statistics only were 
undertaken, and there were no intergroup tests of statistical significance performed. 
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Figure 5. Patient-Reported Satisfaction with OnabotulinumtoxinA Treatment for 
Chronic Migraine 
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b. Stratified by onabotulinumtoxinA treatment history (n=1070) 
  
NOTE: Data on prior use of onabotulinumtoxinA for chronic migraine were available for 1136 patients out of the 1160 patients in the analysis 
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Tables 
Table 1. Reasons for Discontinuing OnabotulinumtoxinA Treatment Prior to Completing 52-week Observation Period 
 UK 
(N=422) 
Germany 
(N=287) 
Sweden 
(N=219) 
Spain 
(N=232) 
Overall 
(N=1160) 
Discontinued Study 163 (38.6) 111 (38.7) 44 (20.1) 28 (12.1) 346 (29.8) 
Reasons for Discontinuation, n (%)* 
Lack of efficacy† 77 (18.2) 55 (19.2) 18 (8.2) 14 (6.0) 164 (14.1) 
Other‡ 25 (5.9) 13 (4.5) 15 (6.8) 3 (1.3) 56 (4.8) 
Side effect/other health problem 22 (5.2) 11 (3.8) 4 (1.8) 2 (0.9) 39 (3.4) 
Lost to follow-up 18 (4.3) 12 (4.2) 1 (0.4) 3 (1.3) 34 (2.9) 
Treatment successful/migraines subsided† 17 (4.0) 9 (3.1) 1 (0.4) 1 (0.4) 28 (2.4) 
Treatment too expensive 14 (3.3) 2 (0.7) 1 (0.4) 2 (0.9) 19 (1.6) 
Inconvenient to come in for treatment visits 6 (1.4) 8 (2.8) 4 (1.8) 0 (0.0) 18 (1.5) 
Injections too painful 6 (1.4) 10 (3.5) 1 (0.4) 0 (0.0) 17 (1.5) 
Concerned about risks 3 (0.7) 6 (2.1) 1 (0.4) 2 (0.9) 12 (1.0) 
Injections took too much time 0 (0.0) 3 (1.0) 2 (0.9) 1 (0.4) 6 (0.5) 
*More than one response was allowed; categories are not mutually exclusive; 312 patients provided ≥1 reason why treatment was discontinued and 34 patients were lost to follow-up. 
† “Lack of efficacy” and “Treatment successful/migraines subsided” were categories determined from manual review of the Other category free-text responses, provided by 238 patients. 
‡ UK: 9 patients reported they were getting or seeking treatment on the National Health Service program; 4 reported they were no longer eligible for treatment based on the NICE guidelines; 3 reported 
a pregnancy; 2 reported adverse effects; 2 moved away or transferred to another physician; 1 reported travel distance was too far; 1 reported treatment was ineffective; 1 was deceased; 2 reported 
other reasons; Germany: 4 patients reported travel distance was too far; 3 reported a pregnancy; 2 reported adverse effects; 1 moved away or transferred to another physician; 3 reported other reasons; 
Sweden: 2 patients moved away or transferred to another physician; 1 reported adverse effects; 1 reported a pregnancy; and 11 reported unknown or other reasons; Spain: 1 patient reported adverse 
effects; 1 moved away or transferred to another physician; 1 was deceased.
Table 2. Baseline Patient Demographics and Clinical Characteristics, of Overall Analysis 
Population and Treatment-Naïve Patients 
 Treatment 
Naïve 
Population 
(N=556)* 
Overall 
Analysis 
Population 
(N=1160) 
Mean (SD) age, years  46.3 (11.97) 46.6 (11.8) 
Min, max 20,79 19, 79 
Female, n (%) 449 (80.8) 977 (84.2) 
White†, n (%) 542 (97.5) 1134 (97.8) 
Mean (SD) BMI, kg/m2 25.2 (4.8) 25.4 (5.1) 
Min, max 16, 44 15, 55 
Headache diagnosis history‡, n (%) 
Chronic migraine or transformed 
migraine 
470 (84.5) 995 (85.8) 
Migraine 298 (53.6) 599 (51.6) 
Medication overuse** 143 (25.7) 286 (24.7) 
Tension headache 76 (13.7) 165 (14.2) 
Chronic daily headache 49 (8.8) 116 (10.0) 
Chronic tension-type headache 22 (4.0) 52 (4.5) 
Intractable/refractory migraine/headache 13 (2.3) 47 (4.1) 
Menstrual headache/migraine 21 (3.8) 43 (3.7) 
Cluster headache 14 (2.5) 27 (2.3) 
Stress headache 14 (2.5) 26 (2.2) 
New daily persistent headache 2 (0.4) 8 (0.7) 
Sinus headache 4 (0.7) 8 (0.7) 
Hemicrania continua 3 (0.5) 6 (0.5) 
Other 21 (3.8) 40 (3.4) 
Baseline headache medication(s)† 
Acute, n (%) 
0 82 (14.7) 155 (13.4) 
1 208 (37.4) 436 (37.6) 
2 152 (27.3) 323 (27.8) 
≥3 114 (20.5) 246 (21.2) 
Preventive, n (%) 
0 277(49.8) 564 (48.6) 
1 172 (30.9) 338 (29.1) 
2 75 (13.5) 187 (16.1) 
≥3 32 (5.8) 71 (6.1) 
Acute and preventive, n (%) 
At least 1 acute and at least 1 preventive 235 (42.3) 509 (43.9) 
Unknown 6 (1.1) 12 (1.0) 
 
*Treatment naïve patients had not received onabotulinumtoxinA for the treatment of chronic migraine prior to the 
study. 
†White is defined differently by country: United Kingdom, white includes English, Welsh, Scottish, Irish, British, 
Gypsy or Irish Traveler, or any other white background; Germany, white includes white/Caucasian. 
‡Includes all headache diagnoses included in the patient’s medical record; more than one response allowed; 
categories are not mutually exclusive 
**Includes any diagnosis of medication overuse headache, rebound headache, or medication/analgesic overuse 
Table 3. OnabotulinumtoxinA Treatment Utilization Characteristics Stratified by Treatment Session 
 Treatment 1 
(N=1160) 
Treatment 2 
(N=1034) 
Treatment 3  
(N=885) 
Treatment 4  
(N=712) 
Treatment 5  
(N=210) 
Treatment 6  
(N=15) 
Total number of sites injected across muscle areas 
Right side, n 1160 1034 884 711 210 15 
Median 15 15 15 15 15 15 
Min, Max 5, 30 4, 29 4, 34 4, 30 4, 30 12, 17 
Left side, n 1160 1034 884 711 210 15 
Median 15 15 15 15 15 15 
Min, Max 5, 30 3, 26 3, 34 4, 32 4, 32 12, 22 
Midline*, n 1095 977 834 680 198 15 
Median 1 1 1 1 1 1 
Min, Max 1, 6 1, 6 1, 5 1, 4 1, 4 1, 3 
Total dose across muscle areas 
Right side, n  1160 1034 884 711 210 15 
Median 75 75 75 75 75 75 
Min, Max 30, 146 25, 145 20, 162 20, 146 20, 146 30, 131 
Left side, n 1160 1034 884 711 210 15 
Median 75 75 75 75 75 75 
Min, Max 30, 160 6, 175 6, 180 20, 180 20, 180 30, 116 
Midline*, n 1095 977 835 681 198 15 
Median 5 5 5 5 5 5 
Min, Max 3, 30 3, 30 3, 120 3, 150 3, 25 5, 25 
Needle length†,‡, n (%) 
0.5 in / 1.25 cm 850 (73.3) 798 (77.2) 672 (75.9) 546 (76.7) 163 (77.6) 10 (66.7) 
1.0 in / 2.5 cm 111 (9.6) 76 (7.4) 82 (9.3) 67 (9.4) 45 (21.4) 0 (0.0) 
Other 279 (23.8) 221 (21.4) 186 (21.0) 147 (20.6) 37 (17.6) 5 (33.3) 
*Includes only procerus and “other” midline muscle areas 
†More than one response allowed; categories are not mutually exclusive 
‡Sweden, Germany, and Spain have needles 1.25 cm and 2.5 cm in length; United Kingdom has needle lengths of 0.5 inch and 1 inch. 
Table 4. Muscle Areas Injected with OnabotulinumtoxinA Stratified by Treatment Session 
Muscle areas injected, 
n(%)* 
Treatment 1 
(N=1160) 
Treatment 2 
(N=1034) 
Treatment 3 
(N=885) 
Treatment 4 
(N=712) 
Treatment 5 
(N=210) 
Treatment 6  
(N=15) 
Right side 
Frontalis 1154 (99.5) 1027 (99.3) 876 (99.0) 704 (98.9) 208 (99.0) 15 (100) 
Corrugator 1131 (97.5) 1006 (97.3) 872 (98.5) 701 (98.5) 206 (98.1) 15 (100) 
Occipitalis 1128 (97.2) 1011 (97.8) 870 (98.3) 703 (98.7) 204 (97.1) 15 (100) 
Temporalis 1155 (99.6) 1031 (99.7) 878 (99.2) 706 (99.2) 207 (98.6) 15 (100) 
Trapezius 1129 (97.3) 1008 (97.5) 864 (97.6) 697 (97.9) 205 (97.6) 15 (100) 
Cervical paraspinal 1091 (94.1) 960 (92.8) 820 (92.7) 655 (92.0) 196 (93.3) 15 (100) 
Masseter 4 (0.3) 12 (1.2) 18 (2.0) 8 (1.1) 3 (1.4) 1 (6.7) 
Other 129 (11.1) 123 (11.9) 103 (11.6) 91 (12.8) 44 (21.0) 4 (26.7) 
Left side 
Frontalis 1154 (99.5) 1027 (99.3) 876 (99.0) 705 (99.0) 208 (99.0) 15 (100) 
Corrugator 1130 (97.4) 1005 (97.2) 872 (98.5) 701 (98.5) 206 (98.1) 15 (100) 
Occipitalis 1128 (97.2 994 (96.1) 859 (97.1) 703 (98.7) 204 (97.1) 15 (100) 
Temporalis 1154 (99.5) 1014 (98.1) 868 (98.1) 707 (99.3) 207 (98.6) 15 (100) 
Trapezius 1129 (97.3) 993 (96.0) 854 (96.5) 697 (97.9) 205 (97.6) 15 (100) 
Cervical paraspinal 1091 (94.1) 944 (91.3) 810 (91.5) 655 (92.0) 196 (93.3) 15 (100) 
Masseter 4 (0.3) 12 (1.2) 18 (2.0) 8 (1.1)  3 (1.4)  1 (6.7) 
Other 131 (11.3) 123 (11.9) 101 (11.4) 89 (12.5) 46 (21.9) 5 (33.3) 
Midline 
Procerus 1095 (94.4) 977 (94.5) 834 (94.2) 680 (95.5) 198 (94.3) 15 (100) 
Other 18 (1.6) 19 (1.8) 11 (1.2) 10 (1.4) 3 (1.4) 1 (6.7) 
*More than one response allowed; categories are not mutually exclusive. 
 Table 5. Summary of adverse events and treatment-related adverse events 
 
UK 
(N=422) 
Germany 
(N=287) 
Sweden 
(N=219) 
Spain 
(N=232) 
All patients 
(N=1160) 
Patients with ≥1 adverse event, n 
(%) 
197 (46.7) 123 (42.9) 86 (39.3) 72 (31.0) 478 (41.2) 
Incidence per 1000 patient 
months (95% CI) 
68.8 (59.5–79.1) 65.3 (54.3–77.9) 45.7 (36.5–56.4) 31.8 (24.9–40.1) 53.8 (49.0–58.8) 
Serious adverse events, n (%) 20 (4.7) 16 (5.6) 16 (7.3) 9 (3.9) 61 (5.3) 
Treatment discontinued due to 
adverse events, n (%) 
27 (6.4) 16 (5.6) 5 (2.3) 3 (1.3) 51 (4.4) 
Special interest adverse events, n (%) 
Worsening of migraine 41 (9.7) 19 (6.6) 12 (5.5) 29 (12.5) 101 (8.7) 
Intractable migraine 2 (0.5) 8 (2.8) 2 (0.9) 8 (3.4) 20 (1.7) 
Hypersensitivity 11 (2.6) 1 (0.3) 4 (1.8) 1 (0.4) 17 (1.5) 
Dysphagia 3 (0.7) 1 (0.3) 0 (0.0) 1 (0.4) 5 (0.4) 
Fatal adverse events, n (%) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.4) 2 (0.2) 
Treatment-related adverse events 
Patients with ≥1 treatment-related 
adverse events, n (%) 
138 (32.7) 88 (30.7) 39 (17.8) 26 (11.2) 291 (25.1) 
Incidence per 1000 patient 
months (95% CI) 
42.1 (35.3–49.7) 40.2 (32.3–49.6) 16.7 (11.8–22.8) 9.9 (6.4–14.5) 27.9 (24.7–31.2) 
Serious treatment-related adverse 
events, n (%) 
1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (<0.1) 
Special interest treatment-related adverse events, n (%) 
Worsening of migraine 28 (6.6) 10 (3.5) 7 (3.2) 1 (0.4) 46 (4.0) 
Intractable migraine 0 (0.0) 3 (1.0) 0 (0.0) 2 (0.9) 5 (0.4) 
Hypersensitivity 7 (1.7) 0 (0.0) 2 (0.9) 1 (0.4) 10 (0.9) 
Dysphagia 3 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.3%) 
Fatal treatment-related adverse 
events, n (%) 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
*Treatment-naïve patients have not previously received onabotulinumtoxinA for the treatment of chronic migraine. 
 
  
Table 6. Treatment-Related Adverse Events Reported by ≥1% of the Treatment-Naïve or Overall Analysis Population 
Adverse Event, n (%) 
Treatment-Naïve Patients 
(N=556)* 
Overall 
(N=1160) 
Neck pain 30 (5.4) 51 (4.4) 
Eyelid ptosis 24 (4.3) 47 (4.1) 
Muscular weakness 16 (2.9) 31 (2.7) 
Headache 14 (2.5) 26 (2.2) 
Musculoskeletal stiffness 14 (2.5) 23 (2.0) 
Migraine 12 (2.2) 34 (2.9) 
Facial paresis 7 (1.3) 15 (1.3) 
Facial spasm 7 (1.3) 11 (0.9) 
Myalgia 7 (1.3) 11 (0.9) 
Pruritus 7 (1.3) 7 (0.6) 
Musculoskeletal pain 6 (1.1) 10 (0.9) 
*Treatment-naïve patients have not previously received onabotulinumtoxinA for the treatment of chronic migraine. 
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* Practice characteristic categories are not mutually exclusive; more than one response was allowed. 
 
  
Supplementary Table 1. OnabotulinumtoxinA Treatment Utilization Characteristics Stratified by Treatment Session for 
Treatment-Naïve Patients* 
 Treatment 1 
(N=556) 
Treatment 2  
(N=491) 
Treatment 3  
(N=393) 
Treatment 4  
(N=313) 
Treatment 5  
(N=103) 
Treatment 6  
(N=11) 
Total number of sites injected across muscle areas 
Right side, n 556 491 392 313 103 11 
Median 15 15 15 15 15 15 
Min, max 7, 30 7,28 8, 34 8, 30 11, 30 15, 17 
Left side, n 556 491 392 313 103 11 
Median 15 15 15 15 15 15 
Min, max 8, 30 3, 26 3, 34 8, 32 11 32 15,17 
Midline†, n 522 460 365 296 97 11 
Median 1 1 1 1 1 1 
Min, max 1, 6 1, 4 1, 5 1, 4 1, 4 1, 1 
Total dose across muscle areas 
Right side, n  556 491 392 313 103 11 
Median 75 75 75 75 75 30 
Min, max 30, 119 30, 120 20, 162 30, 135 30, 100 30, 95 
Left side, n 556 491 392 313 103 11 
Median 75 75 75 75 75 30 
Min, max 30 ,119 6, 120 6, 115 30, 135 30, 130 30, 95 
Midline,† n 522 460 366 296 97 11 
Median 5 5 5 5 5 5 
Min, max 3, 30 3, 15 3, 120 3, 10 3, 8 5, 5 
Needle length,‡,** n (%) 
0.5 in / 1.25 cm 406 (73.0) 369 (75.2) 299 (76.1) 243 (77.6) 82 (79.6) 7 (63.6) 
1.0 in / 2.5 cm 63 (11.3) 40 (8.1) 44 (11.2) 37 (11.8) 23 (22.3) 0 (0.0) 
Other 132 (23.7) 119 (24.2) 84 (21.4) 63 (20.1) 19 (18.4) 4 (36.4) 
*Treatment-naïve patients have not previously received onabotulinumtoxinA for the treatment of chronic migraine. 
†Includes only procerus and “other” midline muscle areas 
‡More than one response allowed; categories are not mutually exclusive 
**Sweden, Germany, and Spain have needles 1.25 cm and 2.5 cm in length; United Kingdom has needle lengths of 0.5 inch and 1 inch in length. 
Supplementary Table 2. Muscle Areas Injected with OnabotulinumtoxinA Stratified by Treatment Session, for Treatment-
Naïve Patients* 
 Treatment 1 
(N=556) 
Treatment 2 
(N=491) 
Treatment 3 
(N=393) 
Treatment 4 
(N=313) 
Treatment 5 
(N=103) 
Treatment 6  
(N=11) 
Right side† 
Frontalis 556 (100) 490 (99.8) 390 (99.2) 312 (99.7) 103 (100) 11 (100) 
Corrugator 554 (99.6) 485 (98.8) 388 (98.7) 311 (99.4) 103 (100) 11 (100) 
Occipitalis 540 (97.1) 477 (97.1) 386 (98.2) 312 (99.7) 103 (100) 11 (100) 
Temporalis 556 (100) 491 (100) 392 (99.7) 312 (99.7) 103 (100) 11 (100) 
Trapezius 550 (98.9) 486 (99.0) 389 (99.0) 311 (99.4) 103 (100) 11 (100) 
Cervical paraspinal 543 (97.7) 473 (96.3) 379 (96.4) 301 (96.2) 100 (97.1) 11 (100) 
Masseter 1 (0.2) 4 (0.8) 8 (2.0) 3 (1.0) 2 (1.9) 1 (9.1) 
Other 66 (11.9) 62 (12.6) 51 (13.0) 48 (15.3) 26 (25.2) 1 (9.1) 
Left side† 
Frontalis 556 (100) 490 (99.8) 390 (99.2) 312 (99.7) 103 (100) 11 (100) 
Corrugator 554 (99.6) 485 (98.8) 388 (98.7) 311 (99.4) 103 (100) 11 (100) 
Occipitalis 539 (96.9) 472 (96.1) 383 (97.5) 312 (99.7) 103 (100) 11 (100) 
Temporalis 555 (99.8) 487 (99.2) 390 (99.2) 313 (100) 103 (100) 11 (100) 
Trapezius 550 (98.9) 482 (98.2) 387 (98.5) 311 (99.4) 103 (100) 11 (100) 
Cervical paraspinal 542 (97.5) 469 (95.5) 377 (95.9) 301 (96.2) 100 (97.1) 11 (100) 
Masseter 1 (0.2) 4 (0.8) 8 (2.0) 3 (1.0) 2 (1.9) 1 (9.1) 
Other 66 (11.9) 60 (12.2) 49 (12.5) 47 (15.0) 27 (26.2) 1 (9.1) 
Midline† 
Procerus 522 (93.9) 460 (93.7) 365 (92.9) 296 (94.6) 97 (94.2) 11 (100) 
Other 3 (0.5) 2 (0.4) 2 (0.5) 1 (0.3) 0 (0.0) 0 (0.0) 
*Treatment-naïve patients have not previously received onabotulinumtoxinA for the treatment of chronic migraine. 
†More than one response allowed; categories are not mutually exclusive. 
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Supplementary Table 3. Summary of Adherence to the Treatment Paradigm Over the 
Study Period, Stratified by Country. 
 UK (N=422) Germany 
(N=287) 
Sweden 
(N=219) 
Spain 
(N=232) 
Overall 
(N=1160) 
Followed 
recommended 
treatment 
paradigm, n (%) 
84 (19.9) 21 (7.3) 8 (3.7) 2 (0.9) 115 (9.9%) 
Deviated from 
recommended 
treatment 
paradigm,* n 
(%) 
338 (80.1) 266 (92.7) 211 (96.3) 230 (99.1) 1045 (90.1) 
Treatment paradigm deviation, n (%)† 
Dose 
<155 U 59 (14.0) 160 (55.7) 128 (58.4) 133 (57.3) 480 (41.4) 
>195 U 16 (3.8) 1 (0.3) 19 (8.7) 18 (7.8) 54 (4.7) 
Injection Sites 
<31 sites 48 (11.4) 106 (36.9) 76 (34.7) 132 (56.9) 362 (31.2) 
>39 sites 13 (3.1) 11 (3.8) 13 (5.9) 8 (3.4) 45 (3.9) 
Dosing interval 
58 
 
<11 weeks 13 (3.1) 18 (6.3) 66 (30.1) 15 (6.5) 112 (9.7) 
>13 weeks 294 (69.7) 197 (68.6) 141 (64.4) 212 (91.4) 844 (72.8) 
Needle length‡ 77 (18.2) 100 (34.8) 56 (25.6) 66 (28.4) 299 (25.8) 
*If a patient received a treatment that deviated (in dose, injection sites, dosage interval or needle length) from the 
recommended label injection paradigm at any time during the study period the patient was classified as “deviated” 
regardless of other treatment sessions. 
†More than one reason for a deviation from the recommended treatment paradigm was allowed and categories were 
not mutually exclusive. 
‡Needle lengths of 1.25 cm (0.5in) and 2.5cm (1 in) are consistent with the treatment paradigm, other needle lengths 
deviate from the treatment paradigm. 
 
